Trials are already underway investigating the utility of Telaglenastat, a glutaminase (GLS1) inhibitor, in the treatment of several solid tumors, including metastatic renal cell carcinoma, colorectal cancer, non-small cell lung cancer, and triple-negative breast cancer [99]. The gene discussed is GLS; the disease is colorectal cancer.